Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for October 2012
October 1, 2012
- ProStrakan Acquires Breast Cancer Product for the US
- Evotec and Bayer Enter Into Multi-Target Alliance to Fight Endometriosis
- GTx Announces Sale of Fareston
- Abbott Labs Gets New Approval for Its Drug Humira
- Genentech's Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
- James E. Burke, Former Chairman and CEO of Johnson & Johnson, Dies at 87
- Celltex To Initiate New Clinical Program As It Responds To FDA Letter
- FingerPaint Marketing Wins W3 Award
- POZEN Patents Upheld in Treximet Patent Litigation Appeal
October 2, 2012
- Johnson & Johnson Expands Puerto Rico Factories
- Allergan Comments on Order Regarding Permanent Injunction against Merz Pharmaceuticals and Merz Aesthetics
- Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases
- ArQule and Daiichi Sankyo Announce Discontinuation of Phase 3 MARQUEE Clinical Trial in Non-Small Cell Lung Cancer
- Sanofi appoints Dr. Paul Chew, Chief Medical Officer and Head of Global Medical Affairs
- BioInvent focuses its business
- Shionogi and Kotobuki to Enter a License Agreement on KT6-971, a Cholesterol Absorption Inhibitor
- Ablynx Collaborates With Merck to Develop Therapeutic Nanobody Candidates
- Cell Therapeutics Rises on Orphan Drug Decision
- Astellas Enters License Agreement with Janssen to Develop and Commercialize ASP015K, an Astellas? Oral JAK Inhibitor for Immunologic Diseases
October 3, 2012
- Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
- Takeda and Advinus Initiate Multi-Year Drug Discovery Collaboration
- VentiRx Pharmaceuticals Announces Exclusive, Strategic Collaboration for Development of Novel TLR8 Agonist VTX-2337 with Celgene Corporation
- Dainippon Sumitomo Pharma Q1 Net Income Decreases
- Federal Judge Approves Settlement for Abbott Illegally Marketing Depakote
- Abbott's White Stands Behind Exec in Resume Flap
- Celgene Edges Higher on Abraxane Melanoma Study
- Benefits Seen in Hormone Use Early in Menopause
- Parents Suing Pfizer Over Daughter's Birth Defects
October 4, 2012
- Orexo Announces Decision to Explore Strategic Alternatives for Commercialization in the US
- Study in Journal of Medical Economics Shows Palivizumab Cost Effectiveness Using FDA-Approved Dosing and APP Red Book
- Interpol: 80 Arrests over Online Medication Sales
- FDA Takes Action Against Thousands of Illegal Internet Pharmacies
October 5, 2012
- Sanofi Recalls Batches of Typhoid Vaccine; not as Potent as Should be
- Johnson & Johnson Settles Five Risperdal Suits
- The Medicines Company Discontinues Phase 2b Trial of MDCO-2010
- Takeda to Acquire LigoCyte Pharmaceuticals, Inc.
- Anacor Pharmaceuticals Announces That GSK Has Discontinued Clinical Development of GSK2251052
- The Medicines Company Discontinues Phase 2b Trial of MDCO-2010
- FTC Seeks U.S. Supreme Court Review in AndroGel "Pay-for-Delay" Case
- Cubist Announces Management Change
- FDA Update: Budeprion XL 300 mg Not Therapeutically Equivalent to Wellbutrin XL 300 mg
- Watson Receives Approval from European Commission for Pending Actavis Acquisition
- Human SARS Virus Genomic Replikin Count Rises to the Level that Preceded the 2003 Lethal SARS Outbreak
October 8, 2012
- Diamyd Medical divests U.S. gene therapy company
- Stroke Drug Looks Promising in Human Trial; Bigger Study Next, Docs Say
- Alzheimer's Update in the Works
- Express Scripts Joins Qsymia (Phentermine And Topiramate Extended-Release) Certified Home Delivery Pharmacy Network
- ImaginAb and Lundbeck to Collaborate in Neurodegeneration
- Revance Therapeutics Regains All Worldwide Rights to Its Botulinum Toxin Products
- AstraZeneca and Ardelyx Announce Worldwide Licensing Deal for NHE3 Inhibitor Programme for Complications of Renal Disease, Including Diabetes-Induced Renal Disease
- CEL-SCI CEO Defends Lead Drug's Lengthy Development Timeline, Hints At "Big" Upcoming Catalyst
- Targacept Takes Further Actions to Align Resources with Corporate Objectives
- Delphi Genetics Grants Merck License for the Use of the StabyExpress System
- BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement
- Merger Creates Largest Independent Healthcare Cross-Cultural Marketing Firm
- Chameleon Communications International Joins The Healthcare Consultancy Group
October 9, 2012
- FingerPaint Leases 395 Broadway
- Merck to Move Global Headquarters Within New Jersey
- Savient Pharmaceuticals' Impressive Run May Continue Higher
- Amicus Therapeutics Could Double On Positive Phase 3 Data
- Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development
- Sanofi and Massachusetts General Hospital Launch Oncology Research Collaboration
- Ahead of the Bell: Eli Lilly Shares Continue Climb
- Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation
- Pieris Achieves First Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics
October 10, 2012
- New Report Reveals Programs That Promote Healthy Ageing Can Help Reduce Rising Health Costs1
- Sudler & Hennessey Creates A Unique Strategic Role Across China and Japan
- Aeras Signs Agreement with GSK to Jointly Advance TB Vaccine
- Merck Plans to Initiate Phase III Clinical Trial With HDM AIT in North America
- Pluristem CEO: Little Chance of Failure
- Oxford BioMedica Announces Update on TroVax Development Strategy
- Senator Calls for Stronger Federal Oversight of Compounding Pharmacies That Manufacture Drugs
October 11, 2012
October 12, 2012
- J&J 3Q Report to Focus on Pharmaceutical Business
- Sector Wrap: Diabetes Drug Makers
- Merck Serono Launches ? 1 Million Research Grant for Multiple Sclerosis Innovation
October 15, 2012
- AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus
- Pharmaron Forms Strategic Partnership with AstraZeneca to Accelerate Drug Discovery
- Xenoport Extends Slump After Analyst's Downgrade
- Analyst Downgrades Lilly Shares to 'Underperform'
- Pharmacyclics Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial
- Fishawack Scientific Communications hits the mark for compliance with clients
October 16, 2012
- Swiss Roche Posts 7 Percent Rise in 3Q Drug Sales
- Johnson & Johnson Reports 2012 Third-Quarter Results:
- Forest Laboratories, Inc. Reports Fiscal Year Second Quarter 2013 GAAP Earnings Per Share of $0.08
- New Report Questions Science Behind Flu Vaccine Efficacy And Use Policy
- Roche Posts 7 Percent Rise in 3Q Drug Sales
- Theravance and Merck Sign Cardiovascular Disease Collaboration
- Roche Group posts strong sales growth in the third quarter
- FTC Places Conditions on Watson Pharmaceutical's Proposed Acquisition of Actavis
- MMG Partners with Remedy Health Media to Bolster Clinical Trial Enrollment
- Enzo Biochem Reports Fourth Quarter Results and Announces Realignment Program Expected to Reduce Annualized Costs $6 Million Commencing with Fiscal First Quarter
October 17, 2012
- Pfizer Says Chantix Met Goals in Depression Study
- Wolters Kluwer Health to Acquire Health Language, Inc., a Leader in the Medical Terminology Management Market
- Abbott Reports Double Digit Earnings Per Share Growth in the Third Quarter
- Charles River Laboratories Enters Strategic Partnership with AstraZeneca
- Johnson & Johnson Rejects Calls to Break Up
- Abbott Labs 3Q Profit Up Without Year-Ago Charges
- MMG Partners with Remedy Health Media to Bolster Clinical Trial Enrollment
October 18, 2012
- Actelion Announces Nine Months 2012 Financial Results
- Baxter Delivers Solid Financial Performance in Line with Guidance for Third Quarter 2012
- BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge
- Abbott Lays Off 550 in Run-up to Spinoff
October 19, 2012
- Isis Trading Halts as FDA Reviews Key Drug's Risks
- AMRI Announces Five-Year Extension of API Supply Agreement With Shire
- Teva Fires 65 Employees at California Plant
- Millennium Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis
- European Medicines Agency Finalises Review of Recent Published Data on Cardiovascular Safety of NSAIDs
- European Medicines Agency Recommends Approval of First Higher-strength Insulin for Treatment of Patients with Diabetes Mellitus in the EU
- European Medicines Agency Reviews Hypothesis on Pandemrix and Development of Narcolepsy
- VIVUS Receives Formal Decision From CHMP
October 22, 2012
- Pfizer To Acquire NextWave Pharmaceuticals, Inc.
- Ligand to Receive $2 Million Milestone Payment from Merck Triggered by Initiation of Phase 2b/3 Trial of Dinaciclib
- Dr. Reddy's Laboratories Limited Intends to Make a Recommended Public Offer for OctoPlus N.V.
- Lilly Reports on Late-Stage Diabetes Drug Studies
October 23, 2012
- Bayer Settling Yaz Injury Lawsuits Despite Being Cleared in Patent Probe
- Results from Five Phase III Studies Presented for GSK's Two Candidate Quadrivalent Influenza Vaccines
- Watson Receives Favorable Court Decision Regarding Generic Actos Approval
- Watson Sells Stake in Latin American Drugmaker
- Ligand Pharma Getting $2M Payment from Merck
- European Medicines Agency Starts Infringement Procedure to Investigate Roche?s Alleged Non-Compliance With Pharmacovigilance Obligations
- Sanofi Oncology and BMT InfoNet Join Forces to Raise Awareness of Stem Cell Transplants for Blood Cancers
- Purohit Navigation Facilitates Charitable Drug Donation from Sagent
- Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Abbott
- Thalidomide's Uneasy Return
- Ironwood and AstraZeneca Announce Linaclotide Collaboration for China
- IMS Study Identifies Six Critical Levers to Improve Medicine Use and Avoid $500 Billion in Unnecessary Annual Healthcare Spending
- Mylan Files Expedited Motion in Relation to Pioglitazone
- Isis Pharmaceuticals To Receive $1.1 Million From Alnylam
- FingerPaint Marketing Honored By American Marketing Association
- Lavoie Group Issues White Paper: Solving the Unique Problems of Orphan Drug Communications
October 24, 2012
- FDA Declines United's Drug Application
- Gilead's 3Q Profit Slips on Acquisition Costs
- Lilly Reports Third-Quarter 2012 Results
- AnGes Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma for Exclusive Marketing Rights of Collategene in the United States
- Bristol-Myers Squibb Reports Third Quarter 2012 Financial Results
- Shire Enters into Novel Research Collaboration with Italian-based Telethon's Institute of Genetics and Medicine for Rare Diseases
- Gilead Sciences Announces Third Quarter 2012 Financial Results
- Innovative Treatment for Cystic Fibrosis Patients, Tobi Podhaler (Tobramycin Inhalation Powder) Receives Positive Draft Guidance From Nice
- Fujifilm Kyowa Kirin Biologics to Initiate Development of Biosimilar of Bevacizumab, An Anti-VEGF Humanized Monoclonal Antibody Which Has Impressive Therapeutic Effects for Cancers Such As Colorectal Cancer
- Eli Lilly 3Q Profit Climbs 7 Pct, Revenue Slides
- Isis Pharma Gets $1.1M Payment From Alnylam
- NIH stops treatment arm in the Look AHEAD Trial: Interpretation and Implications
October 25, 2012
- Recently Launched Products Support Novartis Sales in Third Quarter, Offsetting Patent Expiry; Pharmaceuticals Well-Positioned with Further Pipeline Progress
- Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
- DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
- Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter
- Shire on Track for Double Digit Full Year Earnings Growth
- Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
- McKesson to Purchase PSS World Medical, Inc. in a Transaction Valued at $2.1 Billion
- Sanofi: Q3 2012 Business EPS Reflects Patent Expirations Growth Platforms Reached over 70% of Sales
- AstraZeneca PLC Third Quarter and Nine Months Results 2012
- AstraZeneca Rues Loss of Drug Exclusivity
- Novartis Confident in Safety and Efficacy of its Seasonal Influenza Vaccines Produced in Italy
- Angus Russell to Retire in 2013: Dr Flemming Ornskov to Succeed as Chief Executive
- Whistleblower's extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
October 26, 2012
- Merck Announces Third-Quarter 2012 Financial Results
- Tengion Provides Patient Update on its Neo-Urinary Conduit Clinical Program
- Amgen Closes Deal With Financial Firm to Open New Biotech Company
- Pfizer 3Q Report to Focus on Pipeline, New Drugs
- Watson Confirms FDA Denies Appeal Related to Prochieve NDA for the Prevention of Preterm Birth
- Boehringer Ingelheim to Pay $95 Million to Resolve False Claims Act Allegations
- Forest Laboratories, Inc. Announces Settlement Agreement with Hetero Labs Ltd. in BYSTOLIC Patent Litigation
- Watson Receives FDA Approval for Generic Actos
October 29, 2012
- Pfizer to Cut 300 Jobs, Mostly at Montreal Office
- CHUGAI PHARMACEUTICAL -License Agreement of SGLT2 Inhibitor 'CSG452' in Japan
- Pfizer Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to November 1, 2012 Due To Expected Severe Weather Conditions
- Patheon Announces Refinancing in Connection with Acquisition of Banner Pharmacaps
- Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio
- Shionogi to Hand Over AIDS Drug Sales Rights to ViiV
- AstraZeneca Begins a New Global Study of Faslodex (fulvestrant) Injection in Patients with Hormone Receptor-Positive Advanced Breast Cancer
- Sir Christopher Gent to Retire As Glaxo Chief
- Moroney & Gill, Inc. Wins New Healthcare Account with PuraCap Pharmaceutical LLC
